# CFB Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *CFB* gene encodes Complement Factor B, a critical serine protease zymogen and the catalytic subunit of the alternative pathway's C3 and C5 convertases (C3bBb and C3bBbC3b), essential for innate immunity and pathogen clearance.
- *CFB* is located within the highly polymorphic MHC Class III region on chromosome 6p21.33, with its expression tightly regulated by inflammatory cytokines (IFN-γ, TNF-α) via promoter elements like GAS, ISRE, and NF-κB binding sites.
- Gain-of-function mutations in *CFB*, particularly in the vWFA domain (e.g., K323E, F286L), are pathogenic hotspots for atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) by increasing C3 convertase stability and activity.
- Protective *CFB* variants (e.g., R32Q, L9H) in the CCP1 domain are associated with reduced risk of age-related macular degeneration (AMD) and IgA nephropathy by attenuating alternative pathway activation.
- Biallelic loss-of-function mutations in *CFB* cause a rare inborn error of immunity, leading to recurrent invasive infections with encapsulated bacteria like *Streptococcus pneumoniae* due to absent alternative pathway activity.
- *CFB* is a validated therapeutic target, with small-molecule inhibitors like LNP023 (iptacopan) and RNA-based therapeutics (siRNA) demonstrating efficacy in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy.

---

## Executive Summary & Key Metadata

The **CFB** gene (Complement Factor B) encodes a 93-kDa single-chain glycoprotein that serves as the catalytic subunit of the alternative pathway (AP) C3 convertase (C3bBb) and C5 convertase (C3bBbC3b) of the complement system. CFB is a serine protease zymogen that, upon cleavage by Factor D (FD) into Ba and Bb fragments, forms the enzymatic core of the AP convertases. This pathway constitutes an evolutionarily ancient arm of innate immunity, providing rapid, antibody-independent recognition and opsonization of pathogens, immune complex clearance, and inflammatory modulation. Beyond its canonical extracellular roles, CFB has been implicated in intracellular complement ("complosome") signaling, metabolic reprogramming, and tissue-specific pathologies including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and various malignancies.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | CFB |
| **UniProt Accession** | P00751 |
| **Representative PDB ID** | true (e.g., 2OK5, 1RRK, 1WNR) |
| **Chromosomal Locus** | 6p21.33 (MHC Class III region) |
| **Primary Molecular Function** | Serine-type endopeptidase activity; alternative complement pathway C3/C5 convertase subunit |
| **Disease & Pathology Associations** | aHUS, C3G, AMD, IgA nephropathy, systemic lupus erythematosus, rheumatoid arthritis, pneumococcal meningoencephalitis, paroxysmal nocturnal hemoglobinuria (PNH), various cancers |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The human *CFB* gene is located on the short arm of chromosome 6 at band **6p21.33**, embedded within the **major histocompatibility complex (MHC) Class III region**. This genomic neighborhood is one of the most gene-dense and polymorphic regions of the human genome, containing numerous genes involved in immune function, including complement components C2, C4A, C4B, tumor necrosis factor (TNF), and lymphotoxin. The *CFB* gene spans approximately **6.3 kb** of genomic DNA and is oriented in a head-to-tail arrangement with the adjacent *C2* gene, from which it is separated by only ~500 bp of intergenic sequence. This close physical linkage has profound evolutionary and clinical implications, as regulatory elements may be shared, and genetic variants in one gene can influence the expression of the other.

The *CFB* gene consists of **18 exons** and **17 introns**, with the translation initiation codon located in exon 1 and the stop codon in exon 18. The genomic structure is highly conserved across mammals, as demonstrated by comparative analyses in sheep (*Ovis aries*) and pigs (*Sus scrofa*), where the exon-intron organization and the flanking MHC class III syntenic blocks are preserved. The 5' untranslated region (UTR) is relatively short (~50 bp), while the 3' UTR is approximately 1.2 kb and contains multiple AU-rich elements (AREs) that contribute to post-transcriptional regulation of mRNA stability.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *CFB* lacks a canonical TATA box but contains a **CCAAT box** and several **GC-rich regions** that serve as binding sites for the transcription factor **Sp1** (Specificity Protein 1). This TATA-less promoter architecture is characteristic of constitutively expressed "housekeeping" genes, yet *CFB* expression is highly inducible by inflammatory cytokines. The promoter region contains multiple **interferon (IFN) response elements**, including a **gamma-interferon activation site (GAS)** and an **interferon-stimulated response element (ISRE)**. These elements mediate transcriptional activation by **STAT1** (Signal Transducer and Activator of Transcription 1) and **IRF1** (Interferon Regulatory Factor 1) in response to IFN-γ, a primary inducer of CFB synthesis in hepatocytes, macrophages, and fibroblasts.

Additional regulatory elements include binding sites for **NF-κB** (Nuclear Factor kappa-light-chain-enhancer of activated B cells), which mediates induction by TNF-α and IL-1β, and for **C/EBP** (CCAAT/Enhancer-Binding Protein) family members. The promoter also contains a **glucocorticoid response element (GRE)**, allowing for modulation by corticosteroids. Epigenetic regulation through **histone acetylation** and **DNA methylation** at the *CFB* locus has been documented, particularly in the context of tissue-specific expression and disease states. For instance, hypermethylation of the *CFB* promoter has been associated with reduced expression in certain cancer cell lines, while histone deacetylase inhibitors can upregulate CFB transcription.

### 1.3 Enhancer Elements and Long-Range Chromatin Interactions

Chromatin conformation capture studies (Hi-C, 3C) have revealed that the *CFB* promoter engages in long-range interactions with several enhancer elements located within the MHC class III region. Notably, a **super-enhancer** region approximately 50 kb upstream of *CFB* has been identified that coordinates the expression of multiple complement genes, including *C2*, *CFB*, and *C4*. This regulatory hub is bound by the transcription factors **RUNX1**, **GATA3**, and **FOXP3** in immune cells, suggesting cell-type-specific regulation. In hepatocytes, the liver-enriched transcription factors **HNF1α** and **HNF4α** bind to distal enhancers and promote high-level CFB expression, consistent with the liver being the primary source of circulating CFB.

### 1.4 Alternative Splicing and Isoforms

The *CFB* gene undergoes **alternative splicing** that generates multiple mRNA isoforms, although the functional significance of most remains incompletely characterized. The canonical transcript (NM_001710.6) encodes the full-length 764-amino acid preproprotein. Alternative splicing events include:

- **Exon 2 skipping**: Produces a transcript lacking the signal peptide, potentially encoding a cytoplasmic or nuclear variant of CFB. This isoform has been detected in intracellular compartments and may participate in the "complosome" — an intracellular complement system that regulates T-cell metabolism and survival.
- **Exon 12 skipping**: Results in a frameshift and premature stop codon, generating a truncated protein that may act as a dominant-negative regulator of complement activation.
- **Retained intron 6**: Produces a transcript targeted for nonsense-mediated decay (NMD), representing a potential regulatory mechanism for controlling CFB protein levels.

Single-cell RNA sequencing (scRNA-seq) studies have identified cell-type-specific isoform usage, with macrophages and fibroblasts expressing distinct CFB splice variants. The functional implications of these isoforms in health and disease remain an active area of investigation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human CFB protein is synthesized as a single-chain polypeptide of 764 amino acids, including a 25-amino-acid signal peptide that is cleaved upon translocation into the endoplasmic reticulum. The mature secreted protein (739 amino acids, ~93 kDa) is organized into three distinct structural and functional domains, arranged from the N-terminus to the C-terminus:

1. **Complement Control Protein (CCP) Modules (residues 1–206)**: Three tandem CCP modules (also known as short consensus repeats, SCRs) that mediate binding to C3b. Each CCP module consists of approximately 60 amino acids folded into a β-sandwich structure stabilized by two disulfide bonds. The CCP modules are essential for the formation of the C3bB complex and for the proper orientation of the catalytic domain.

2. **von Willebrand Factor Type A (vWFA) Domain (residues 207–444)**: A globular domain of approximately 240 residues that adopts a Rossmann-fold topology, consisting of a central parallel β-sheet flanked by α-helices. The vWFA domain contains a **metal ion-dependent adhesion site (MIDAS)** that coordinates a divalent cation (Mg²⁺ or Mn²⁺), which is critical for the interaction with C3b. This domain also harbors the **Ba fragment** cleavage site and undergoes significant conformational changes upon C3b binding.

3. **Serine Protease (SP) Domain (residues 445–739)**: The C-terminal catalytic domain, which adopts the canonical chymotrypsin-like serine protease fold. The SP domain contains the catalytic triad consisting of **His501**, **Asp551**, and **Ser674** (numbering based on the mature protein). This domain is responsible for the cleavage of C3 and C5, the key effector functions of the AP convertases.

### 2.2 Three-Dimensional Structure and Conformational Dynamics

High-resolution crystal structures of CFB, both alone and in complex with C3b, have provided detailed insights into its molecular architecture and activation mechanism. The structure of full-length CFB in its zymogen form (PDB: 2OK5) reveals a **closed, inactive conformation** in which the SP domain is docked against the vWFA domain, preventing substrate access to the active site. The CCP modules extend away from the vWFA-SP interface, poised for interaction with C3b.

Upon binding to C3b, CFB undergoes a dramatic **conformational rearrangement**. The cryo-EM structure of the C3bB complex (PDB: 2XWJ) shows that C3b binding induces a ~100° rotation of the vWFA domain relative to the SP domain, exposing the scissile bond (Arg234-Lys235) for cleavage by Factor D. This "open" conformation is stabilized by the MIDAS-mediated interaction between the vWFA domain and the C3b TED domain. Following cleavage, the Ba fragment (residues 1–234) dissociates, leaving the Bb fragment (residues 235–739) bound to C3b. The resulting C3bBb complex is the active C3 convertase, with the SP domain now positioned to cleave C3.

The structure of the C3bBb complex (PDB: 2WIN) reveals that the Bb fragment adopts a **catalytically competent conformation** in which the oxyanion hole is properly formed and the active site is accessible. The complex is stabilized by multiple protein-protein interactions, including contacts between the vWFA domain and the C3b MG domains, and between the SP domain and the C3b CUB domain. The half-life of the C3bBb complex is relatively short (~90 seconds), but it is significantly prolonged by the binding of the positive regulator **Properdin**, which stabilizes the complex and protects it from inactivation by Factor H and Factor I.

### 2.3 Post-Translational Modifications

CFB undergoes several post-translational modifications that are essential for its function:

- **N-linked glycosylation**: CFB contains four potential N-glycosylation sites (Asn-X-Ser/Thr motifs) at positions Asn107, Asn269, Asn320, and Asn466. Glycosylation at these sites is required for proper folding, secretion, and stability of the protein. The glycan structures are predominantly complex-type, with variable sialylation that may influence the half-life of circulating CFB.
- **Disulfide bond formation**: The CCP modules each contain two conserved disulfide bonds (Cys1-Cys3, Cys2-Cys4 pattern), while the SP domain contains one disulfide bond. These bonds are critical for maintaining the structural integrity of the domains.
- **Proteolytic processing**: The conversion of zymogen CFB to the active Bb fragment requires proteolytic cleavage at the Arg234-Lys235 bond by Factor D. This cleavage is the rate-limiting step in AP activation and is tightly regulated.

### 2.4 Interactive 3D Visualizer

For a comprehensive exploration of the CFB protein structure, including domain architecture, active site residues, and conformational states, please use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load CFB (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P00751)

This tool allows users to rotate, zoom, and selectively display individual domains, highlight key residues, and overlay structural information from multiple PDB entries.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Alternative Pathway of Complement Activation

CFB is the central component of the **alternative pathway (AP)** of complement activation, a continuously "tick-over" system that provides immediate defense against pathogens and altered self-cells. The AP is initiated by the spontaneous hydrolysis of the internal thioester bond of C3, generating C3(H₂O). This hydrolyzed C3 binds Factor B, which is then cleaved by Factor D to form the initial fluid-phase C3 convertase, C3(H₂O)Bb. This enzyme cleaves native C3 into C3a (anaphylatoxin) and C3b. Nascent C3b contains a highly reactive thioester that can covalently attach to hydroxyl or amino groups on cell surfaces, marking them for opsonization.

Surface-bound C3b recruits Factor B, forming the C3bB complex. Factor D then cleaves Factor B, releasing Ba and generating the surface-bound C3 convertase, C3bBb. This enzyme cleaves additional C3 molecules, creating a positive feedback amplification loop. The C3 convertase can bind an additional C3b molecule to form the C5 convertase, C3bBbC3b, which cleaves C5 into C5a (potent anaphylatoxin and chemoattractant) and C5b. C5b initiates the assembly of the membrane attack complex (MAC), leading to cell lysis.

### 3.2 Regulation of the Alternative Pathway

The AP is tightly regulated by a network of soluble and membrane-bound proteins that control CFB activity at multiple levels:

- **Factor H (FH)**: A soluble glycoprotein that competes with Factor B for binding to C3b, accelerates the decay of the C3 convertase, and acts as a cofactor for Factor I-mediated cleavage of C3b. FH is the primary regulator of the AP in fluid phase and on host cells.
- **Factor I (FI)**: A serine protease that cleaves C3b into inactive fragments (iC3b) in the presence of cofactors such as FH, C4b-binding protein (C4BP), or membrane cofactor protein (MCP/CD46).
- **Membrane cofactor protein (MCP/CD46)**: A widely expressed transmembrane protein that serves as a cofactor for FI-mediated cleavage of C3b.
- **Decay-accelerating factor (DAF/CD55)**: A glycosylphosphatidylinositol (GPI)-anchored membrane protein that accelerates the decay of C3 and C5 convertases.
- **Complement receptor 1 (CR1/CD35)**: A membrane protein that possesses both decay-accelerating and cofactor activities.

Dysregulation of this pathway, often due to genetic variants in CFB or its regulators, leads to uncontrolled complement activation and is the underlying cause of several diseases, including aHUS, C3G, and AMD.

### 3.3 Intracellular Complement and the "Complosome"

Recent research has revealed that complement components, including CFB, are expressed and function **intracellularly**, constituting a cell-autonomous complement system termed the "complosome". In T cells, intracellular C3 is cleaved by cathepsin L into C3a and C3b, and intracellular CFB is cleaved by Factor D-like proteases to generate Bb. The intracellular C3a binds to the lysosomal C3a receptor (C3aR), while C3b associates with the autophagy-related protein ATG16L1, promoting autophagy and T-cell survival. Intracellular Bb interacts with the mitochondrial protein NDUFA10, modulating oxidative phosphorylation and metabolic reprogramming.

In vascular fibroblasts, an intracellular complement system drives proinflammatory and metabolic reprogramming, contributing to the pathogenesis of pulmonary hypertension. The intracellular CFB expression is induced by mechanical stress and inflammatory cytokines, and its knockdown attenuates the proinflammatory phenotype. These findings expand the functional repertoire of CFB beyond its classical extracellular roles and suggest novel therapeutic targets.

### 3.4 CFB in Immune Evasion and Host-Pathogen Interactions

The AP is a critical defense mechanism against encapsulated bacteria, particularly *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae*. CFB deficiency, whether genetic or acquired, predisposes individuals to recurrent invasive infections by these pathogens. Conversely, many pathogens have evolved mechanisms to subvert the AP by hijacking CFB or its regulators:

- **Streptococcus pyogenes** produces the M protein, which binds FH and C4BP, enhancing the degradation of C3b and preventing opsonization.
- **Staphylococcus aureus** secretes the complement inhibitor SCIN (staphylococcal complement inhibitor), which stabilizes the C3 convertase in an inactive state, preventing C3 cleavage.
- **Neisseria species** express porins that bind FH, promoting resistance to complement-mediated killing.

The *cfb* gene in **Group B Streptococcus (GBS, *Streptococcus agalactiae*)** encodes the CAMP factor, a pore-forming toxin that is distinct from the human CFB gene product but shares the same gene symbol in bacterial nomenclature. The CAMP factor binds to IgG and IgM and enhances the hemolytic activity of staphylococcal β-hemolysin, producing the characteristic "arrowhead" pattern in the CAMP test used for GBS identification. Chromosomal deletions of the *cfb* gene in GBS strains result in a CAMP-negative phenotype, leading to false-negative results in diagnostic tests. This has significant implications for the screening of pregnant women for GBS colonization, as CAMP-negative strains may evade detection and cause neonatal infections.

### 3.5 Protein-Protein Interaction Networks

CFB participates in a complex network of protein-protein interactions that extend beyond the core complement components. Key interactors identified through biochemical and high-throughput studies include:

- **C3 and C3b**: The primary substrate and binding partner, essential for convertase assembly.
- **Factor D**: The activating protease that cleaves CFB.
- **Properdin**: A positive regulator that stabilizes the C3 convertase.
- **Factor H and Factor I**: Negative regulators that control CFB activity.
- **C3aR and C5aR1**: Receptors for the anaphylatoxins generated by CFB-mediated cleavage.
- **NDUFA10**: A mitochondrial complex I subunit that interacts with intracellular Bb.
- **ATG16L1**: An autophagy protein that interacts with intracellular C3b.

STRING and BioGRID databases list over 50 high-confidence physical and functional interactions for CFB, reflecting its central role in the complement network and its emerging functions in cellular metabolism and autophagy.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 CFB Mutations in Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is caused by dysregulation of the AP, often due to genetic variants in complement genes, including CFB. CFB mutations account for approximately 1-4% of aHUS cases and are typically **gain-of-function** mutations that increase the formation or stability of the C3 convertase.

**Hotspot mutations in CFB associated with aHUS:**

| **Mutation** | **Domain** | **Functional Consequence** | **Reference** |
|---|---|---|---|
| **K323E** | vWFA | Increases C3b binding affinity and convertase stability | |
| **F286L** | vWFA | Enhances C3 convertase formation | |
| **K323N** | vWFA | Gain-of-function, increased C3b affinity | |
| **D279G** | vWFA | Increases C3b binding and convertase activity | |
| **P369L** | vWFA | Novel variant, associated with adult-onset aHUS | |
| **R32Q** | CCP1 | Loss-of-function, protective for AMD, but may contribute to aHUS in combination with other variants | |
| **L9H** | CCP1 | Associated with reduced AP activity, protective for AMD | |

The **P369L** mutation, located in exon 8 of the vWFA domain, was identified in a 47-year-old male with adult-onset aHUS. This heterozygous missense variant was predicted to be pathogenic by multiple in silico tools and was associated with low C3 levels, indicating complement consumption. The patient was successfully treated with eculizumab, a monoclonal antibody against C5.

**Combined mutations** in CFB and other complement genes are common in aHUS and influence the clinical phenotype. For example, a patient with a novel CFB variant and a pathogenic COL4A5 variant (associated with Alport syndrome) presented with a renal disease that had features of both C3G and Alport syndrome. This case highlights the importance of comprehensive genetic testing in patients with atypical renal diseases.

### 4.2 CFB Mutations in C3 Glomerulopathy (C3G)

C3 glomerulopathy (C3G) is a group of rare kidney diseases characterized by predominant C3 deposition in the glomeruli, resulting from dysregulation of the AP. CFB mutations, both gain-of-function and loss-of-function, have been implicated in C3G. A familial case of C3 glomerulonephritis was associated with a heterozygous mutation in the CFB gene, leading to increased C3 convertase activity. The disease presented with proteinuria, hematuria, and progressive renal dysfunction, and was resistant to conventional immunosuppressive therapy.

### 4.3 CFB Variants in Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the elderly, and the AP of complement has been strongly implicated in its pathogenesis. Multiple genetic variants in CFB have been associated with AMD risk, with most being **protective** (reducing disease risk).

**Key CFB variants associated with AMD:**

| **Variant** | **Effect** | **Odds Ratio** | **Population** | **Reference** |
|---|---|---|---|---|
| **rs641153 (R32Q)** | Protective | 0.45-0.55 | Multiple | |
| **rs4151667 (L9H)** | Protective | 0.30-0.50 | Multiple | |
| **rs12614 (R32W)** | Risk | 1.2-1.5 | Japanese | |
| **rs4151657** | Risk | 1.3 | Han Chinese | |

The **R32Q** variant (rs641153) is located in the CCP1 domain and results in reduced binding of CFB to C3b, leading to decreased AP activity. This variant is strongly protective against AMD, with an odds ratio of approximately 0.5 in multiple populations. The **L9H** variant (rs4151667) is also protective and is in strong linkage disequilibrium with R32Q.

In contrast, the **R32W** variant (rs12614) is a low-frequency coding variant that increases the risk of exudative AMD in the Japanese population. This variant is located in the same CCP1 domain but has the opposite functional effect, increasing C3b binding and AP activity.

### 4.4 CFB in IgA Nephropathy

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, and AP activation plays a role in its pathogenesis. A functional variant, **rs12614 (R32W)**, in CFB was found to confer a low risk of IgAN in Han Chinese by attenuating AP activation. This variant is the same as the one associated with increased AMD risk in the Japanese population, highlighting the context-dependent effects of CFB variants.

### 4.5 CFB Deficiency and Inborn Errors of Immunity

Biallelic loss-of-function mutations in CFB cause **complement factor B deficiency**, an exceptionally rare inborn error of immunity characterized by recurrent invasive infections with encapsulated bacteria, particularly *Streptococcus pneumoniae*. Patients typically present in childhood with pneumococcal meningitis, sepsis, or pneumonia. The deficiency is associated with absent AP activity, while the classical and lectin pathways remain intact. Diagnosis is confirmed by low or undetectable CFB protein levels and genetic testing.

A case report described a patient with pneumococcal meningoencephalitis who was found to have non-coding CFB variants. Integrated genomic and immunological assays revealed that these variants affected CFB expression and function, leading to impaired AP activity and increased susceptibility to infection. This case underscores the importance of considering non-coding variants in the diagnostic workup of complement deficiencies.

### 4.6 CFB in Other Diseases

- **Rheumatoid Arthritis (RA)**: CFB has been identified as a fibroblast-associated marker in RA, with elevated expression in synovial fibroblasts contributing to inflammation and joint destruction. A SASP-related three-gene panel, including CFB, was found to be reproducible in predicting RA severity.
- **Diabetic Retinopathy (DR)**: Polymorphisms in CFB, along with CFH, have been associated with the risk of DR in type 2 diabetic patients.
- **ANCA-Associated Vasculitis (AAV)**: Common gene variants in CFH/CFHR1-5, C2/CFB, and C3 determine disease susceptibility and severity in AAV.
- **Pneumococcal Meningoencephalitis**: CFB deficiency or dysfunction predisposes to this severe infection.
- **Paroxysmal Nocturnal Hemoglobinuria (PNH)**: CFB is a therapeutic target in PNH, a rare acquired hemolytic disorder caused by somatic mutations in PIG-A.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Evasion of CFB-Mediated Complement

Bacteria have evolved sophisticated mechanisms to evade the AP of complement, many of which target CFB or its regulators:

- **Streptococcus pyogenes**: The M protein binds FH and C4BP, recruiting these negative regulators to the bacterial surface and preventing C3b deposition. Additionally, the secreted protein SIC (streptococcal inhibitor of complement) binds to and inhibits the activity of C3b and CFB.
- **Staphylococcus aureus**: Secretes SCIN, which binds to and stabilizes the C3 convertase (C3bBb) in an inactive conformation, preventing C3 cleavage. SCIN also promotes the dissociation of the Ba fragment, further inhibiting AP activation.
- **Neisseria meningitidis**: The factor H binding protein (fHbp) binds FH, recruiting it to the bacterial surface and downregulating AP activation. Porin A (PorA) also binds FH.
- **Escherichia coli**: The OmpA protein binds FH and C4BP, contributing to serum resistance.

### 5.2 Viral Interactions with CFB

Viruses can also manipulate the complement system to evade immune detection:

- **Herpesviruses**: Several herpesviruses, including herpes simplex virus (HSV) and cytomegalovirus (CMV), encode proteins that mimic complement regulators. HSV glycoprotein C (gC) binds C3b and inhibits the interaction of CFB with C3b, while CMV encodes a protein that binds FH.
- **Poxviruses**: Vaccinia virus and variola virus encode complement control proteins (VCP/SPICE) that possess both decay-accelerating and cofactor activities, inactivating C3b and C4b.
- **Retroviruses**: HIV-1 has been shown to incorporate host complement regulators, including CD55 and CD59, into its envelope, protecting it from complement-mediated lysis.

### 5.3 The CAMP Factor of Group B Streptococcus

The *cfb* gene in Group B Streptococcus (GBS) encodes the **CAMP factor**, a 25-kDa secreted protein that is distinct from the human CFB gene product. The CAMP factor binds to the Fc region of IgG and IgM and acts synergistically with staphylococcal β-hemolysin to lyse erythrocytes, producing the characteristic "arrowhead" pattern in the CAMP test. This test is widely used for the presumptive identification of GBS in clinical microbiology laboratories.

**Chromosomal deletions of the *cfb* gene** in GBS strains result in a CAMP-negative phenotype, leading to false-negative results in both the CAMP test and molecular assays targeting *cfb*. These deletions can be complete or partial and may encompass adjacent genes, affecting other virulence factors. The prevalence of CAMP-negative GBS strains varies by geographic region and has been reported to be as high as 5-10% in some studies. This has significant implications for the screening of pregnant women for GBS colonization, as CAMP-negative strains may evade detection and cause neonatal infections.

The molecular characterization of the *cfb* gene has revealed that it is highly conserved among GBS strains, with >99% nucleotide sequence identity. However, the chromosomal deletions that cause the CAMP-negative phenotype are diverse, with different deletion breakpoints observed in different strains. This genetic heterogeneity complicates the design of molecular diagnostic assays and highlights the need for multi-target approaches.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CFB as a Therapeutic Target

Given its central role in the AP of complement, CFB has emerged as an attractive therapeutic target for diseases characterized by complement dysregulation, including aHUS, C3G, AMD, and PNH. Several strategies are being pursued to inhibit CFB activity:

### 6.2 Small-Molecule Inhibitors

**LNP023 (Iptacopan)**: An orally bioavailable, small-molecule inhibitor of Factor B, developed by Novartis. LNP023 binds to the active site of Factor B and prevents the cleavage of C3 by the C3 convertase. In clinical trials, LNP023 has shown efficacy in PNH, C3G, and IgA nephropathy. It has received FDA breakthrough therapy designation for PNH and is in Phase III trials for C3G and IgAN.

**ACH-4471 (Danicopan)**: A small-molecule inhibitor of Factor D, which is upstream of Factor B in the AP. By inhibiting Factor D, danicopan prevents the cleavage of Factor B and the formation of the C3 convertase. It has been evaluated in clinical trials for PNH and C3G.

### 6.3 Monoclonal Antibodies

**Eculizumab (Soliris)**: A humanized monoclonal antibody against C5 that blocks the cleavage of C5 into C5a and C5b, preventing the formation of the MAC. Eculizumab is FDA-approved for the treatment of aHUS and PNH and has been shown to be effective in patients with CFB mutations. However, it does not directly target CFB and leaves the upstream AP activation intact.

**Ravulizumab (Ultomiris)**: A next-generation anti-C5 antibody with an extended half-life, allowing for less frequent dosing. It is also approved for aHUS and PNH.

**Biosimilars**: Elizaria, a biosimilar of eculizumab, has been used in the treatment of aHUS due to C3 gene mutations in children.

### 6.4 RNA-Based Therapeutics

**VSA012**: A CFB-targeted small interfering RNA (siRNA) developed by Visirna Therapeutics. In a Phase Ib study, VSA012 demonstrated a favorable safety profile and sustained efficacy in PNH patients. The siRNA is delivered via a GalNAc conjugate for hepatocyte-specific targeting, reducing CFB expression in the liver and thereby decreasing AP activity.

### 6.5 Gene Therapy

Gene therapy approaches for complement disorders are in early stages of development. The goal is to deliver a functional copy of the defective gene (e.g., CFB in CFB deficiency) or to deliver inhibitors of complement components. Adeno-associated virus (AAV) vectors are the most commonly used delivery vehicles, and preclinical studies have shown promise in animal models of complement-mediated diseases.

### 6.6 Pharmacogenomic Considerations

Genetic variants in CFB can influence the response to complement-targeted therapies. For example, patients with gain-of-function CFB mutations may require higher doses of eculizumab or may benefit from combination therapy with a Factor B inhibitor. Conversely, patients with loss-of-function CFB variants may be at increased risk of infection when treated with complement inhibitors. Pharmacogenomic testing for CFB variants may therefore be useful for guiding treatment decisions.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **Description** |
|---|---|---|
| **NCBI Gene** | 629 | Gene ID for human CFB |
| **Ensembl** | ENSG00000204371 | Ensembl gene ID |
| **UniProt** | P00751 | Primary protein accession |
| **RCSB PDB** | 2OK5, 2XWJ, 2WIN, 1RRK, 1WNR | Representative structures |
| **HGNC** | 1037 | HGNC symbol and ID |
| **OMIM** | 138470 | Mendelian inheritance and disease associations |
| **ClinVar** | Various | Clinical variants and pathogenicity classifications |
| **STRING** | 9606.ENSP00000265847 | Protein-protein interaction network |
| **BioGRID** | 108940 | Physical and genetic interactions |
| **Gene Ontology (GO)** | GO:0004252, GO:0006956, GO:0005576 | Molecular function, biological process, cellular component |
| **KEGG** | hsa04610 | Complement and coagulation cascades pathway |
| **Reactome** | R-HSA-174734 | Complement cascade pathway |
| **GWAS Catalog** | Various | Genome-wide association study associations |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Description** |
|---|---|---|
| **Molecular Function** | GO:0004252 | Serine-type endopeptidase activity |
| **Molecular Function** | GO:0008201 | Heparin binding |
| **Biological Process** | GO:0006956 | Complement activation |
| **Biological Process** | GO:0006958 | Complement activation, classical pathway |
| **Biological Process** | GO:0016064 | Immunoglobulin mediated immune response |
| **Biological Process** | GO:0045087 | Innate immune response |
| **Cellular Component** | GO:0005576 | Extracellular region |
| **Cellular Component** | GO:0005615 | Extracellular space |
| **Cellular Component** | GO:0070062 | Extracellular exosome |

---

## 8. Mermaid Diagram: CFB in the Alternative Complement Pathway

```mermaid
sequenceDiagram
    participant C3 as C3 (Native)
    participant C3H2O as C3(H2O)
    participant FB as Factor B (CFB)
    participant FD as Factor D
    participant C3b as C3b
    participant C3bB as C3bB Complex
    participant C3bBb as C3 Convertase (C3bBb)
    participant C3bBbC3b as C5 Convertase (C3bBbC3b)
    participant C5 as C5
    participant MAC as Membrane Attack Complex

    C3->>C3H2O: Spontaneous hydrolysis (tick-over)
    C3H2O->>C3H2O: Binds Factor B (CFB)
    C3H2O->>C3H2O: Factor D cleaves CFB
    C3H2O->>C3b: Cle

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)